Biocon enters into agreement for development, commercialization of rh-Insulin for US Market

17 Mar 2016 Evaluate

Biocon, through its wholly owned subsidiary Biocon SA, has entered into a co-development and commercialization agreement with Laboratories PiSA S.A. de C.V (PiSA) of Mexico for generic recombinant human insulin (rh-insulin) for the US market.

This is a cost and profit sharing agreement with Biocon SA being responsible for clinical development, regulatory approvals, and commercialization of the product in the US. The drug substance will be made by Biocon while the drug product will be made by PiSA at its facility in Mexico.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

366.55 -9.45 (-2.51%)
20-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.00
Dr. Reddys Lab 1166.90
Cipla 1377.85
Zydus Lifesciences 872.95
Lupin 2166.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×